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Colorectal cancer is one of the major causes of death worldwide. In Canada, colon cancer is the 
third most commonly diagnosed cancer. Fortunately, 90% of deaths and cases of colon cancer are 
preventable. If detected at an early stage, it can be cured. There are different challenges in 
developing a drug for cancer treatments which include tumor selectivity, target specificity, drug 
efficacy, and overcoming multi-drug resistance (MDR). Designing target specific molecules has 
brought better success in developing new anticancer agents. Various anticancer targets have been 
explored for this purpose. Among them, metalloproteinases such as methionine aminopeptidase 2 
(MetAP2) play a major role in being an anticancer drug target. This research focuses on the 
investigation of novel curcumin analogs displaying both MetAP2 inhibitory and cytotoxic 
properties for further development as anticancer agents. 
Purpose 
The purpose of this study is to identify promising cytotoxic curcumin analogs as inhibitors of 
MetAP2 expression and investigate their potential as novel anticancer drug candidates. 
Method 
The compounds were selected from docking studies against the enzyme MetAP2. They were 
evaluated for their physicochemical properties through SwissADME scores.  The best compounds 
among the screened compounds were then considered for preclinical evaluations through screening 
against the colon cancer cell lines HCT116, and HT29, and the normal colon cell line CRL1790 in 
vitro for their cytotoxic profiles. The best 2 compounds (NC 1768 and NC 1773) were analysed for 
their inhibitory property against MetAP2 expression in the HT29 cell line using western blot 
analysis. The Student’s t-test for paired data and Dunnett’s post hoc test with p<0.05 were 




One hundred thirty compounds were docked against MetAP2 enzyme, out of these the top 10 
compounds that showed good results for their physicochemical properties assessment were taken 
for cytotoxic evaluation. Among the 10 compounds, 2 compounds (NC 1768 and NC 1773) had 
good IC50 profiles, and they were analysed using western blot. The western blot indicated that 
MetAP2 protein expression was reduced by NC 1773 in the HT29 cell line. Dunnett’s post hoc test 
showed significance at p<0.05 for the treatment protocol of NC 1773 in comparison with control 
(cells with absence of treatment). The correlations between the cytotoxicity (IC50) and the 
physicochemical properties was undertaken using Student’s t-test for paired data. The bivariate 
linear models with logarithmic transformations that were taken for interpretation were linear model, 
linear-log model, and log-log model. The statistical analysis performed using Student’s t-test for 
paired data was not significant with p>0.05 in all 3 bivariate linear models.  
Conclusion 
The compound NC 1773 has shown excellent results in docking and western blot analysis. It has 
an ideal IC50 profile and predicted bioavailability which warrants further investigation for the 





I would like to extend my heartfelt and sincere gratitude to Emeritus Professor Jonathan R. 
Dimmock, College of Pharmacy and Nutrition and Distinguished Professor Rajendra K. Sharma, 
Department of Pathology and Laboratory Medicine, College of Medicine for their continued support, 
insightful approach, invaluable guidance, encouragement, and positive environment for research. 
They have been instrumental in steering the thesis in the right direction, owing to their vast 
experience in this research area. I am grateful for their trust, constructive comments, patient support, 
and expertise during my experimental and writing process. 
I would like to thank my advisory committee members, Dr. Brian Bandy and Dr. Suresh Tikoo, for 
providing their invaluable expertise and advice. I am thankful to my graduate chair, Dr. Ekaterina 
Dadachova, for being a constant guide and motivator throughout my degree.  
I would like to express my utmost gratitude to Dr. Umashankar Das and Dr. Swagatika Das. I 
greatly appreciate your assistance with my research. Thank you for the endless laughter and life 
advice you have given me. You have taught me so much and I am forever grateful to you.  
I express my sincere gratitude to Dr. Meena Sakharkar for her timely advice and skillful guidance. 
I would like to extend my deep sense of gratitude to my colleagues at Cancer Research Cluster, 
notably Dr. Ravi Shankar Singh for his prompt suggestions and kindness.  
I thankfully acknowledge the College of Pharmacy and Nutrition, and the College of Medicine at 
the University of Saskatchewan for financially supporting my graduate studies and for giving me 
the right environment to accomplish my educational endeavors. I duly recognize Maunders McNeil 
Foundation Inc. for funding this project. 
Finally, I would like to wholeheartedly thank my father (Dr. Hari Narayan Pati), my mother (Sujata 
Pati), my sister (Sukriti Pati), and my loving husband (Jagannath Prasad Dash) for their 
immeasurable love, support, and encouragement throughout this endeavor. I would like to 
acknowledge the love and support of my parents, their motivation and faith in me was my greatest 
strength. A huge thanks to my parents for their sacrifices and reasons beyond number and scope; I 
would not be where I am without them. Special thanks to my sister, for understanding that this 
project has cut into our time together, and for continuing to make me laugh and enjoy our moments. 
I’m particularly grateful for your encouragement dear sister when situations were rough, you have 
been the pillar to my accomplishments. She has supported and inspired me on this excellent 
adventure. And a heartfelt thanks to my beloved husband Jagannath Prasad Dash, for his endless 
love, support, care, optimism, generosity, and patience during my program.  






This thesis is dedicated to...  
 
...my inspiring father, Dr. Hari Narayan Pati 
 my caring mother, Sujata Pati 
 my loving sister, Sukriti Pati 
my beloved husband, Jagannath Prasad Dash 
and my dear son, Ishaan Dash  
vi 
 
TABLE OF CONTENTS 
 




TABLE OF CONTENTS………………..…………………………….…………………….…..vi 
LIST OF TABLES…………………………………………………….…………….…...……..viii 
LIST OF FIGURES…………………….……………………………..……….….……………..ix  
LIST OF ABBREVIATIONS…………………………………….………………………………x  
CHAPTER 1- LITERATURE REVIEW…………………..……………….…..……………….1  
1.1 Introduction………………………..………………………….……..…………………1  
1.2 Methionine aminopeptidases………………………………….……..…………………1  
1.3 MetAP2 and Cancer ………………………………..……………..………….…….….3 
1.4 MetAP2 inhibitors as anticancer agents……………………...………………………...4 
1.5 Curcumin analogs and cancer……………………………...…………………………11 
1.6 Curcumin analogs and MetAP2 inhibitors………………...………………….………17 
CHAPTER 2 - HYPOTHESIS AND OBJECTIVES.................................................................19 
2.1 Hypothesis………..………………………………………………………….………..19  
2.2 Objectives………..……………………………………………………………..……..19 
CHAPTER 3 - MATERIALS...……………….……………….………………………………..21 
CHAPTER 4 - METHODOLOGY...……………….……………….….……..………………..23 
4.1 Literature survey and database generation ….….….……………..…………………..23 
4.2 Docking studies ………………….…..…………………………..…….……………..23 
4.2.1 The accession of the target protein………………………………………….23 
4.2.2 Molecular docking using Schrödinger..………….………....…………..…..24 
vii 
 
4.3 Physicochemical properties evaluation..……………………………………………...25 
4.4 Cytotoxic studies of the best MetAP2 inhibitors……………………………………...25 
4.5 Cell Lysate Preparation……………………………………………………………….27 
4.6 Western blot analysis of MetAP2 expression…………………………………………27  
 4.6.1 Protein Estimation…………………………………………………………..27 
 4.6.2 SDS Page………..…………………………………………………………..27 
 4.6.3 Western blot analysis………………………………………………………..27 
4.7 Statistical Analysis ………………………………………………..………….….…...28 
CHAPTER 5 - RESULTS AND DISCUSSION…..………………………….……………..….29 
5.1 Database and docking studies………..…...………………………….……………….29  
5.2 Physicochemical properties evaluation…...………………………….……………….30 
5.3 Biological evaluation.....................................................................................................35 
 5.3.1 Cytotoxic Studies...........................................................................................35 
 5.3.2 Western blot analysis.....................................................................................40 
5.4 Ligand receptor interaction...........................................................................................45 
5.5 Statistical analysis of correlation between cytotoxicity and physiochemical  
      properties……………………………………………………………………………...52 
CHAPTER 6 - CONCLUSIONS...………..……………………..……..……………………….53  
CHAPTER 7 - FUTURE SCOPE………………..…………..…………..………….......……...55 











LIST OF TABLES 
  
 
Table 5.1  Docking Score and physicochemical properties evaluation.……………………....31-34 
Table 5.2  Cytotoxic profiles of top 10 compounds.… ………………………………………36-37 
Table 5.3  Comparison of cytotoxicity profiles. …………………………………………………38 
Table 5.4  Correlation between the cytotoxic properties...…………………………………….…52  
ix 
 
LIST OF FIGURES 
             
Figure 1.1  Proposed reaction mechanism of MetAP in E. coli.…….………………………….....2 
Figure 1.2  Fumagillin and its derivatives demonstrate potent MetAP2 inhibition..……...…..…..5 
Figure 1.3  Structure of MetAP2 inhibitors …………………………………….…………….…...7 
Figure 1.4  M8891 in the active site of MetAP2……….….…………………....……………...9-10 
Figure 1.5  Structure of cytotoxic curcumin analogs ………………………….…….…………..12 
Figure 1.6  Curcumin-based thiol alkylators …….…………………....…………….………...…15 
Figure 1.7  3, 5-Bis (arylmethylene)-1-(N-arylmaleamoyl)-4-piperidones ………….……….….16 
Figure 1.8  4-Boc-piperidone chalcones ……….………….…………………....………………..17 
Figure 1.9  Structural modification of curcumin to NC 2213……….……………….………..…18 
Figure 5.1  Western blot analysis of effects on MetAP2 expression in HT29.....………………..42 
Figure 5.2  Comparision of effects protein expression…….…………………....……………..…43 
Figure 5.3  Quantification of western blot..…....………….…………………....……………..…44 
Figure 5.4  Structure of MetAP2 recombinant protein….………….…………………....………45 
Figure 5.5  Ligand receptor interaction of compound NC 1773….………………....…………...46 
Figure 5.6  Ligand receptor interaction of compound NC 1768….………………....…………...47 
Figure 5.7  Visual representations of the compounds NC 1773 and NC 1768.…….……..……..49 
Figure 5.8  Docked view of NC 1773 and NC 1768 at the active site of MetAP2.…….…….50-51  
x 
 
LIST OF ABBREVIATIONS 
5-FU   5- fluorouracil 
ADME  Absorption, distribution, metabolism, and excretion 
BSA    Bovine serum albumin 
DMSO   Dimethyl sulfoxide 
GI50   Half growth inhibitory concentration 
GLIDE  Grid-based Ligand Docking with Energetics 
GScore  Glide score 
GSH   Glutathione 
GST   Glutathione S-transferase 
h-MetAP2  Human-MetAP2 
IC50   Half maximal inhibitory concentration 
IFD   Induced Fit Docking 
MDR    Multidrug resistance    
MetAP   Methionine aminopeptidase 
MetAPs  Methionine aminopeptidases 
MMP   Mitochondrial membrane potential 
MW   Molecular weight 
NFκB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NMT   N-myristolytransferase 
PBS   Phosphate Buffer Saline 
xi 
 
pp60c-src  Proto-oncogene tyrosine protein kinase  
PVDF   Polyvinylidene difluoride membrane 
RIPA   Radioimmunoprecipitation assay 
ROS   Reactive oxygen species 
SDS   Sodium dodecyl sulfate 
SRB   Sulforhodamine B 
TBS-T   Tris-buffered saline with 0.1% Tween 20 
TCA   Trichloroacetic acid 
TPSA   Topological polar surface area  
vdW   van der Waals 
VEGF   Vascular endothelial growth factor 
XP   Extra precision 
1 
 
CHAPTER – 1  
LITERATURE REVIEW 
1.1 Introduction 
Colorectal cancer is one of the major causes of death worldwide. In Canada, colon cancer is the 
third most diagnosed cancer. Fortunately, 90% of deaths and cases of colon cancer are 
preventable.1 If detected at an early stage, it can be cured. There are different challenges in 
developing drugs for cancer treatments, these include tumor selectivity, target specificity, drug 
efficacy, and overcoming multidrug resistance (MDR). The designing of target-specific molecules 
has brought better success in developing new anticancer agents. Various anticancer targets have 
been explored for this purpose; enzymes or biological processes that include tyrosine kinase, 
metalloproteinases, cyclooxygenases, and antisense oligonucleotides are the major anticancer drug 
targets. Among them, metalloproteinases such as methionine aminopeptidases (MetAPs) perform 
a major role in being an anticancer drug target.2 This proposal mainly focuses on the investigation 
of novel anticancer molecules targeting MetAPs. Efforts are underway to diagnose cancer at an 
early stage by understanding molecular mechanisms involved in the genesis of colon cancer and 
developing new strategies for cancer prevention, early detection, and development of an anticancer 
drug for treatment. 
1.2 Methionine aminopeptidases 
Methionine is one of the 20 proteinogenic essential amino acids required for many biological 
processes such as polyamine synthesis and DNA methylation.3 Almost all proteins have a common 
process of amino acid terminal modification for nascent polypeptides occurring inside the cell. 
Metalloproteinases like methionine aminopeptidase (MetAP) perform the basic function of 
removal of the essential amino acid methionine from the nascent proteins unblocked N- termini.4, 
5 The maturation of many proteins takes place after the vital step of removal of the N-terminal 
initiator methionine from nascent polypeptides. This process occurs either co-translationally or 
post-translationally for the formation of a new protein.  The two proposed reaction mechanisms 
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for MetAP in E. coli as depicted in Figure 1.1 are; one, the tetrahedral intermediate is stabilized 
by Glu204 and the metal center, and second, the tetrahedral intermediate is stabilized by His178 
and the metal center.6 In the mechanisms depicted below E- enzyme, E.S- enzyme+ substrate, 
E.TS- enzyme+ Transition state of substrate, and S- substrate. This process occurs either co-
translationally or post-translationally for the formation of a new protein. In eukaryotes, 80% of 
proteins go through the removal of the N-termini methionine as an initiation method for the protein 
translation process. This initiator methionine is responsible for the stability, compartmentalization, 
and activity of the proteins inside the cell.3, 7  
 
Figure 1.1: Proposed reaction mechanism of MetAP in E. coli.6 In this mechanism E- 
enzyme, E.S- enzyme+ substrate, E.TS- enzyme+ Transition state of substrate, and S- substrate. 
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The MetAP exists in two forms that catalyze the methionine cleavage. MetAP1 differs from 
MetAP2 as it is devoid of a disulfide bond in the crystal structure of the enzyme.8 This single 
disulfide bond exists in disulfide (oxidized) and thiol (reduced) states and influences enzyme 
function thus regulating the enzymatic function of MetAP2.9 Loss of activity of MetAP2 causes 
proliferation arrest at G1, whereas inhibition of the activity of MetAP1 leads to cell cycle arrest at 
G2/M in the mammalian cells.8  
MetAP co-translationally removes the N-terminal methionine from nascent proteins. This N-
terminal methionine is often cleaved when the second residue in the primary sequence is small and 
uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human MetAP2 
toward Met-Val peptides suggests that it is responsible for the processing of proteins containing 
N-terminal Met-Val and Met-Thr sequences in vivo, as it’s consistently two orders of magnitude 
higher than that of MetAP1.10 
1.3 MetAP2 and Cancer 
Methionine is crucial for tumor cell multiplication and survival.11-13 Thus, limiting its availability 
can be a very useful approach to control the proliferation of tumor cells. Since the discovery of the 
two forms of MetAPs, MetAP2 has been gaining a lot of attention for its role as an anti-angiogenic 
target in anticancer drug development through expression in cancer cells. It has shown to be 
overexpressing itself in a variety of cancers.11, 14 Such an observation was made by our laboratory 
on MetAP2 in human colorectal cancers. Selvakumar et. al. had demonstrated that high expression 
of MetAP2 in human colorectal cancer contributes to the development of colon cancer.15 Also, a 
myristoylated oncoprotein (pp60c-src) is overexpressed along with MetAP2 in tumor cells when 
compared to normal cells.15 Selvakumar et. al. had demonstrated that MetAP2 and N-
myristolytransferase (NMT) genes are upregulated during the malignization of colonic tissues and 
they have a significant correlation as well.15 These results were confirmed by enzyme activity, and 
the MetAP2 expression was significantly higher in Colo320, Colo201, and Colo205 human colon 
cancer cell lines (HCCLs).16   
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1.4 MetAP2 inhibitors as anticancer agents 
Two antiangiogenic compounds,  fumagillin, and ovalicin were found to inhibit MetAP2 by 
binding irreversibly and covalently, leading to cell cycle arrest of endothelial cells at the G1 
phase.17 However there are several other mechanisms by which these compounds may act. For 
example, fumagillin affects angiogenesis both in vitro and in vivo by inhibiting the FGR1/ PI3K/ 
AKT pathways. It has also been shown to inhibit the activity of Bcl-2 and telomerase for metastasis 
in rats, the growth of hepatocellular carcinoma, and metastasis in mice for the growth of colorectal 
cancer in vivo.18 In that study, fumagillin increased MetAP2 mRNA expression. In vitro, 
fumagillin was shown to upregulate 71 genes and down-regulate 143 genes along with a significant 
decrease in the tube formation and proliferation of human umbilical vein endothelial cells 
(HUVEC).  
The removal of the N-terminal initiator methionine from nascent polypeptides is facilitated by the 
key active site residues and a binuclear metal center in a non-processive manner.  The binuclear 
metal center is bound by monodentate (His-171, Glu-204) and bidentate (Asp-97, Asp-108, Glu-
235) ligands, and the nucleophile during catalysis is the metal-bridging water or hydroxide ion. 
Despite the molecule being overall symmetric, the active site is asymmetrically located with the 
methionine binding pocket. The binding pocket is primarily generated by residues from the N-
terminal domain.19 Several authors have argued on MetAP2 activity in the presence of iron,20, 21 
cobalt,21, 22 manganese,23, 24 and zinc.24 H178 and H79 are histidine residues that seem to be 
conserved in all mechanisms mentioned to date, implying their importance in the catalytic activity 
of MetAP2.25 X-ray crystallographic data suggest H79 helps position the methionine residue in the 
active site and transfer a proton to the newly exposed N-terminal amine.26  
TNP-470, a semi-synthetic analog of fumagillin (Figure 1.2) was found to be 50 times more potent 
than the parent compound, with an IC50 (half maximal inhibitory concentration) of 50 pM being 
both safe and effective in preclinical trials as well as in several animal models for the treatment of 
solid tumors.27 It activates the p53 pathway causing cyclin-dependent kinase inhibition and 
p21Cip1/Waf1 expression leading to the arrest of progression of endothelial cells at the late G1 
phase. It then entered clinical trials in humans for the treatment of AIDS-related Kaposi's sarcoma, 
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metastatic breast cancer, androgen-independent prostate cancer, pediatric solid tumors, 
lymphomas, acute leukemia, advanced squamous cell cancer of the cervix, and metastatic renal 
carcinoma.28-30 An interactive effect was observed in vivo in combination therapy of TNP-470 
along with conventional cytotoxic agents.31-33  
 
Figure 1.2:  Fumagillin and its derivatives demonstrate potent MetAP2 inhibition 
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Using molecular modeling based on structures, four MetAP2 inhibitors (Figure 1.2) IDR-803, 
IDR-804, IDR-805, and CKD-732, with high potency were designed and examined against the 
SNU- 398 hepatoma cell line for their anti-angiogenic effect and capability to inhibit cancer growth 
in vivo.34 Chun et. al. confirmed the ability of these compounds to inhibit cancer growth in vivo 
and identified them as potential anticancer agents.34 
Fumagalone (Figure 1.2), a synthetic analog of fumagillin has an aldehyde group replacing the 
spiroepoxide group, which enables it to both inhibit MetAP2 activity and increase the potency by 
40 to 50 folds with high specificity towards the enzyme as compared to the parent compound.35 
CKD-732 (Figure 1.2), another semi-synthetic analog of fumagillin, exhibited potency for 
antiangiogenic activity both in vitro as well as in vivo. It is 1000 fold more active than the parent 
compound in inducing cell cycle arrest at G1 and suppressing the proliferation of HUVECs. It is 
twice better than fumagillin in increasing the life span in nude mice with human tumor PC-3 
(prostate adenocarcinoma) and nude mice bearing athymic A375-SM. The potential value of 
MetAP2 as a novel therapeutic target was greatly accelerated by the development of novel 
fumagillin analogs with improved pharmacological properties over the parent compound. CKD-
732 and TNP-470 (Figure 1.2) have been examined for oncological trials, but their development 
was terminated because of the adverse events that were a result of their unfavorable 
pharmacokinetics in the clinical trials.17 Therefore, the search for new MetAP2 inhibitors as 




Figure 1.3: Structure of MetAP2 inhibitors 
The need for finding structurally divergent MetAP2 inhibitors led to the discovery of several potent 
lead molecules, compounds 1-4 (Figure 1.3).36-42 In particular, M8891 was found to be a potent 
inhibitor of MetAP2 and is currently under phase-I clinical trials.36 The interaction of M8891 in 
the MetAP-2 binding site is presented in Figure 1.4.  In 1.4A polar interactions are shown to the 
left and the middle portion depicts the lipophilic contacts the compound is making with the 
enzyme; all distances are given in angstroms (Å). The right side of the figure has the M8891 
surface in green and the molecules are in black while the MetAP-2 pocket is in magenta color 
(PDB: 6QED). Figure 1.4B at 2Å represents the hydrogen bonds in blue and halogen bonds in 
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turquoise; the metal interactions are outlined in purple, while the hydrophobic interactions are in 
grey.  
The cyclic tartronic diamide scaffold coordinates in a chelating manner for the two manganese 
ions. The halogenated benzyl moiety helps in molecular recognition, and it interacts with MetAP2 
with van der Waals contacts. The lactam oxygen interacts with the imidazoles of His331 and 
His339 and Mn2+ ion 508. The amide moiety makes two interactions; one, the amide oxygen 
coordinates with the buried Mn2+ ion 507, and second, the amide NH interacts with the imidazole 
of His231. His231 imidazole also makes lipophilic contacts with the tetrahydroquinolinone bound 
to the lactam nitrogen and the benzylamide residue. The tetrahydroquinolinone residue makes 
several van der Waals (vdW) interactions at Leu447, His231, Leu328, and a hydrogen bond with 
Asn329 and the lactam-NH. The fluorine interacts with the side chain of Ala414, while the chlorine 
interacts with Ile338. Also, the chlorine is involved in a reverse cation−π interaction with the 
imidazole moiety of His339. 
Several MetAP2 inhibitors crystals structures have been published in the last 5 years in RCSB 
PDB (http://www.rcsb.org/pdb/home/home.do). Among them, 5D6F,43 5JFR,38 5YKP,44 5LYW,45 
6QEF,46 and 6QED36 are some of the noteworthy co-crystals structures with resolutions ranging 
from 1.5- 1.8 Å. Among the various published co-crystals structures of MetAP2, we have chosen 
6QED as the receptor for our research based on its excellent activity and properties. It is a 
reversible MetAP2 inhibitor with an IC50 of 15 nM, it is well-tolerated and has exhibited antitumor 
efficacy in the mouse glioblastoma model. Figure 1.4C depicts the affinity of M8891 in the 
receptor pocket at 4Å rendering it to be a good inhibitor of MetAP2. MetAP2 is a monomer 











Figure 1.4: M8891 in the active site of MetAP2. 1.4A shows the polar (green) and 4B shows 
lipophilic (orange) interactions with distances in (Å). 1.4C illustrates M8891 in the binding 
pocket of the enzyme (PDB:6QED) and its interactions with amino acid residues (π-π stacking- 




Target-specific drug discovery has been considered very successful in developing preclinical drug 
candidates for further drug development. An extensive review of MetAP2 inhibitors was published 
from Dr. Sharma’s laboratory focusing on the involvement of this enzyme in the regulation of 
various apoptotic factors.2 Another review by Chiu et. al. discussed about the role of disulfide 
bond of the MetAP2 enzyme that exists in oxidized and reduced states in tumor cells.9 Stressing 
the normal cells through oxygen or glucose deprivation results in the enzyme being in an oxidized 
state. The oxidized and reduced isoforms have different catalytic efficiencies for hydrolysis of 
MetAP2 peptide substrates. Their findings indicated that MetAP2 is post-translationally regulated 
by an allosteric disulfide bond, which in turn is responsible for substrate specificity and catalytic 
efficiency. Continuous efforts have been made to develop structurally divergent new MetAP2 
inhibitors to enhance drug specificity and treat drug-resistant colon cancers.     
1.5 Curcumin analogs and Cancer 
There has been a significant interest in curcumin-based compounds as anticancer agents in the last 
two decades. Several research studies have been published on the broad biological activities of 
curcumin which include its anti-inflammatory,47, 48 anti-oxidant,49 anti-mutagenic,49  
antimicrobial50, anti-cystic fibrosis51, and anticancer50, 52, 53 properties. However, the clinical 
potential of curcumin is limited by its extremely low oral bioavailability, due to its chemical 
instability.54 In the last two decades, a large number of curcumin analogs have been developed to 
increase pharmacokinetic properties (Figure 1.5).55-63  New curcumin analogs have shown 
improved effects as free radical scavengers64 and cytotoxic agents.65 Some also have shown to be 




Figure 1.5: Structure of cytotoxic curcumin analogs 
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EF24, a synthetic analog of curcumin inhibited net cell growth of pancreatic cancer cells with 
almost 10- to 20-fold lower IC50 as compared to curcumin across various cell lines in a 
concentration-dependent manner. In pancreatic carcinoma (MiaPaCa) and patient-derived 
pancreatic ductal adenocarcinoma (Pa03C), EF24 annulled 
the ability of pancreatic cancer cells to form colonies at about 10-fold lower concentrations than 
curcumin.55, 56 5a, and its more soluble analog, 5b are structurally distinct curcumin analogs that 
induced apoptosis in four separate human renal cell carcinoma (RCC) cell lines and human 
melanoma cell lines. They inhibited in vitro generation of myeloid-derived suppressor cells and 
significantly reduced secretion of vascular endothelial growth factor (VEGF) from RCC cell lines 
in a dose-dependent manner.57 Compounds in series 6 had the most potent anticancer activity 
against renal cell carcinoma (ACHN), pancreatic carcinoma (Panc1), non-small cell lung 
carcinoma (Calu1), large cell lung carcinoma (H460), and human colorectal carcinoma (HCT116) 
human cancer cell lines when compared with standard flavopiridol and gemcitabine.58, 59  
A series of curcumin-based diarylheptanoid analogs 7 have been synthesized and tested for anti-
glioblastoma and anti-neuroblastoma effects.60 At 30 µM, therapy with 7 resulted in the number 
of colonies declining by 20–25 percent suggesting that the compound-mediated toxicity of 
hematopoietic cells was not evident in vitro.60 The compound 7 is cytotoxic to the brain and 
peripheral cancers of the nervous system and has enhanced metabolic and pharmacokinetic 
profiles.60 The compound 8, a novel mono-carbonyl curcumin analog with excellent cytotoxicity 
against several cancer cell lines. This is also a potent growth inhibitor of human colorectal cancer 
cells and has been linked with the arrest of cell cycle progression and activation of apoptosis. As 
a multi-targeted agent, 8 causes cancer cell apoptosis by collapsing the mitochondrial membrane 
potential (MMP), increasing the Bax/Bcl-2 ratio, then activating the caspase-9/3 cascade.62, 63 A 
sequence of Knoevenagel condensates were synthesized with clubbing pyrazole carbaldehydes 9 
at the active methylene carbon atom of the curcumin backbone among them 9 was the most active 
analogue that showed substantial anti-cancer activity against the tested cancer cell line. The 
proapoptotic activity of compound 9 has been outstanding through the induction of apoptosis in 
cancer cells. Although the reported effects of cytotoxicity and apoptosis were lower than the 
standard therapy with paclitaxel.61 
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Many curcumin analogs were designed as thiol alkylators that exert cytotoxicity by alkylation of 
cellular thiols with the help of the mercapto group present in cellular constituents.68 They react 
with glutathione (GSH), metallothioneins, cysteine, and a cysteinyl group of enzymes making it a 
molecular target.  Many α, β-unsaturated ketone compounds (thiol alkylators) were designed by 
Dimmock and coworkers as cytotoxic alkylating agents based on the principle of sequential 
cytotoxicity.69 These α, β-unsaturated ketone compounds have been synthesized with a view to 
increasing the sensitivity of tumors towards different anti-cancer drugs by reducing the 
concentration of cellular thiols of tumor cells. The approach of releasing alkylating agents at 
glutathione-rich tumor sites sequentially is described in the theory of sequential cytotoxicity. As 
the amount of glutathione S-transferase (GST) may be higher in tumor cells compared to normal 
cells, α, β-unsaturated ketone compounds are more favorable in decreasing the cellular thiols prior 
to an attack by an anti-cancer drug.69 Thus, making the attack more deleterious to tumor cells than 
normal tissues. α, β-unsaturated ketone compounds as thiol alkylators have been the neoplastic 
agents that have shown the capability of reversing drug resistance as well.69  
A series of N-4-(2-aminoethoxy)phenylcarbonyl derivatives of various 3,5-bis(benzylidene)-4-
piperidones showed potential cytotoxicity for human leukemia (HL-60), human squamous cell 
carcinomas (HSC-2, and HSC-4).70 Among these curcumin-based thiol alkylators, 10 (Figure 1.6) 
was very specific for human HCT116 colon cancer cells. It had antiproliferative effects by 
increasing the concentration of reactive oxygen species (ROS), inhibiting the transport chain of 
electrons, and decreasing the membrane potential of mitochondria. While it exhibited 
antiproliferative effects for human HCT116 cells, it was less toxic for human non-malignant 
(CRL1790) colon cells. It induced apoptosis in human HL-60 cells while activating caspase-3 




Figure 1.6: Curcumin-based thiol alkylator 
Curcumin-derived piperidones have prevailing efficacy in multiple cell lines even at low 
concentrations. Several (11a-c: Figure 1.7) of curcumin-compounds from the three series of novel 
3, 5-bis (arylmethylene)-1-(N-arylmaleamoyl)-4-piperidones inhibited proliferation of human 
Molt 4/C8, lymphoblastic leukemia (CEM) T-lymphocytes, and murine leukemic cells (L1210) as 
well as exhibiting antioxidant properties as well as topoisomerase IIa inhibitory activity.71, 72 
Curcumin analogs displayed 93-280 folds higher potency in comparison with melphalan. These 




Figure 1.7: 3, 5-Bis (arylmethylene)-1-(N-arylmaleamoyl)-4-piperidones 
A recent study by Ocasio-Malavé et. al. brought to light the potential of Boc-piperidone chalcones 
as novel cytotoxic agents against highly metastatic cancer cells.73 Their ability to induce apoptosis, 
decrease the activity of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), and 
cellular proliferation is linked to their cytotoxic activity. While compound 6 exhibited equipotent 
cytotoxicity as cisplatin towards colorectal carcinoma (LoVo) and colon adenocarcinoma (COLO-
205) cell lines and less toxicity towards the normal colorectal (CCD18Co) cell lines; compound 
12 (Figure 1.8) displayed cytotoxicity towards highly metastatic prostate cancer (PC3 and 22RV1) 




Figure 1.8: 4-Boc-piperidone chalcones 
Many of these enones display MDR reverting properties and are well tolerated in a short-term 
toxicity screen in mice.74-76 Therefore, the development of novel 3,5-bis-arylidene-4-piperidone 
derivatives with improved cytotoxic potencies and pharmacokinetic properties may lead to the 
discovery of a novel drug candidate for treating cancers.   
1.6 Curcumin analogs and MetAP2 inhibitors 
A wide range of curcumin-related analogs has been developed by Das et. al. as anticancer and 
antiproliferative agents.77 Several α, β-unsaturated ketones show cytotoxic and anti-cancer 
properties which interact with cellular thiols, and the conversion of enones increases the rate of 
thiol alkylation and cytotoxicity. Figure 1.9 delineates a drug design strategy by Pati et. al. to 
undertake structural modification of curcumin to produce novel synthetic analogs as anticancer 
agents.78 These enones were designed as thiol alkylators having both cytotoxic properties and the 
ability to inhibit the MetAP2 enzyme.79 The dienone pharmacophore is the alkylating active site 





Figure 1.9: Structural modification of curcumin to NC 2213 
NC 2213 (Figure 1.9), is a potent cytotoxic agent [IC50: 1.2 µM against human colorectal 
adenocarcinoma (HT-29) cells] which inhibits Tyr416 phosphorylation of proto-oncogene tyrosine 
protein kinase (pp60c-src) and activating Tyr527 phosphorylation of pp60c-src at the same time, 
causing apoptosis of HT29 cells.78  
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CHAPTER – 2  
 HYPOTHESIS AND OBJECTIVES 
2.1 Hypothesis 
Cytotoxic curcumin analogs displaying potent inhibition of MetAP2 expression can be developed 
as therapeutic agents for treating colon cancer. 
2.2 Objectives 
To identify promising cytotoxic curcumin analogs with the ability to inhibit the MetAP2 protein 
expression and investigate their potential as novel anticancer drug candidates for treating colon 
cancers. 
To accomplish this objective, the project focuses on the following sub-objectives: 
• Literature survey for identifying potent curcumin analogs 
• Creation of a database of potent cytotoxic curcumin analogs 
• MetAP2-ligand docking studies using the database of curcumin analogs: To identify the 
best curcumin analogs that show a good fit in the MetAP2 binding pocket. 
o Docking methodology aims to predict the experimental binding modes and 
affinities of small molecules within the binding site of particular receptor targets 
and is currently used as a standard computational tool in drug design for lead 
compound optimization and in virtual screening studies to find novel biologically 
active molecules. The basic tools of a docking methodology include a search 




• In silico analysis of the leading compounds from docking studies will be taken for 
pharmacokinetic and drug-likeness properties 
o Lipinski et. al. proposed the “Rule of Five”,  the most famous drug-likeness filter, 
which provides four rules to determine whether a molecule is likely to be orally 
well absorbed or not.81 When a compound violates two or more rules, it may not be 
orally active. To be an effective drug, a compound must reach the target in 
sufficient concentration and be present long enough for the biological effect to take 
place. It is believed that drugs or drug candidates tend to have similar distributions 
of physicochemical properties. Hence, based on their respective absorption, 
distribution, metabolism, and excretion (ADME) properties and drug-likeness it 
can be determined if a compound is likely to be an efficient drug nominee. 
• Cytotoxic and biological evaluation in vitro  
o The compounds obtained from the above studies were screened against colon 
cancer cell lines HCT116 and HT29, in vitro. The top 2 compounds were evaluated 
against non-malignant CRL1790 to identify their selective toxicity to tumors as 
compared to non-malignant cells. The best 2 compounds (NC 1773 and NC 1768) 
were analyzed for their inhibitory property against the HT29 cell line using western 
blot analysis. The physicochemical properties of these compounds were evaluated, 
and the best compounds satisfying drug-likeness properties, docking well into 
MetAP2 pocket with good cytotoxicity was considered for further biological 
evaluations.  
• The correlation between cytotoxicity and MetAP2 inhibition of protein expression was 
investigated using statistical analysis using SPSS software.    
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CHAPTER – 3  
MATERIALS 
30% Acrylamide/bis-acrylamide, 37.5:1 (Catalogue#:1610158, Bio-Rad) 
5- Fluorouracil (F6627-1G, Sigma-Aldrich) 
6 Well cell culture plate (Catalogue#: 14-832-11, Thermo Fischer Scientific) 
96 Well cell culture plate (Catalogue#: CS003799, Thermo Fischer Scientific) 
Ammonium Persulphate (A3678, Sigma-Aldrich) 
Blotting grade blocker non fat dry milk (Catalogue#: 1706404XTU, Bio-Rad) 
Bovine serum albumin (PI37525, Thermo Fischer Scientific) 
Bradford dye (Catalogue#: 5000205, Bio-Rad) 
Clarity Western ECL Substrate (Catalogue#: 17005060, Bio-Rad) 
Culture Dish 10mm (Catalogue#: 12-565-91, Thermo Fischer Scientific) 
Dimethyl sulfoxide (D8418, Sigma-Aldrich) 
EMEM media (Catalogue#: 30-2003, ATCC) 
Ethanol (Catalogue#: 001-02-17N) 
Fetal bovine serum (Catalogue#: 12483020, Gibco) 
Glycine (Catalogue#: BP381-5, Thermo Fischer Scientific) 
HRP-linked mouse anti-β-actin antibody (sc-8432, molecular weight- 42 kDa, 1:40,000) (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) 
McCoy’s media (Catalogue#: SH30200.01, Ge Hyclone) 
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Methanol (Catalogue#: A452-4, Thermo Fischer Scientific) 
Penicillin-Streptomycin (Catalogue#: SV30010, Ge Hyclone) 
Phosphate Buffer Saline (Catalogue#: SH3025802, Ge Hyclone) 
Precision plus protein dual color Standards (Catalogue#: 1610374, Bio-Rad) 
Primary antibody: anti-Met-AP2 antibodies (MetAP2 (D3I1H) Rabbit mAb #12547, Cell 
Signaling Technology) 
PVDF membrane (Catalogue#: 1620177, Bio-Rad) 
RIPA buffer (R0278, Sigma-Aldrich) 
Secondary antibody: Anti-rabbit IgG, HRP-linked antibody #7074, Cell Signaling Technology) 
Sodium dodecyl sulfate (Catalogue#:1610302, Bio-Rad) 
Sulforhodamine B dye (230162, Sigma-Aldrich) 
TEMED (Catalogue#:1610800, Bio-Rad) 
Trichloroacetic acid (T9159, Sigma-Aldrich) 
Tris base (Catalogue#: BP152-5 Thermo Fischer Scientific) 
Trizma base (T1503, Sigma-Aldrich) 
Trypsin (Catalogue#: 252000-56, Gibco) 
Tween 20 (Catalogue#:1706531, Bio-Rad)  
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CHAPTER – 4  
METHODOLOGY 
4.1 Literature survey and database generation 
In order to find the potent MetAP2 inhibitors and cytotoxic curcumin analogs from the literature, 
use was made of SciFinder,82 PubMed,83 MEDLINE,16 and ScienceDirect.33 Then a library of 
cytotoxic curcumin analogs was created using Schrodinger.84 The library constituted of a total of 
130 compounds. 
4.2 Docking studies  
The database of curcumin analogs was docked in the MetAP2 binding site using Schrodinger.84 
This was carried out by complexing the potential curcumin analogs in the h-MetAP2 co-crystal 
structure 6QED.36 The curcumin analogs were then ranked according to their docking scores. For 
this study, the co-crystal structure of h-MetAP2 complexed with M8891 (Figure 1.4) (PDB code: 
6QED) was used and the ligand M8891 was removed to dock the compounds in the database. The 
higher the docking score the better it fits in the MetAP2 active site. The top 10 compounds were 
taken for biological screening.   
4.2.1 The accession of the target protein 
The protein of interest is human MetAP2 which is a polypeptide from a unique class of 
metalloproteases.5 The removal of the N-terminal initiator methionine from nascent polypeptides 
is facilitated by the key active site residues and a dinuclear metal center in a non-processive 
manner. The three-dimension crystal structure of human MetAP2 (PDB: 6QED) in complex with 
a co-crystallized ligand was retrieved from RCSB PDB 
(http://www.rcsb.org/pdb/home/home.do).36   
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4.2.2 Molecular docking using Schrödinger  
• The protein model was optimized before docking using the Protein Preparation Wizard85 
in Schrödinger Maestro Suite 2014 software (Schrödinger Suite 2014-3 Protein 
Preparation Wizard; Epik version 2.9, Schrödinger, LLC, New York, NY, 2014; Impact 
version 6.4, Schrödinger, LLC, New York, NY, 2014; Prime version 3.7, Schrödinger, 
LLC, New York, NY, 2014). During the optimization process, any inconsistencies in 
the structure such as missing hydrogen atoms, incorrect bond orders, the orientation of 
the different functional groups of the amino acids were checked and corrected. The 
prepared protein was then used for Induced Fit Docking.  
• The structures of the compounds were drawn on Maestro (Schrödinger Release 2020-3: 
Maestro, Schrödinger, LLC, New York, NY, 2020.) and saved as a separate entry to make 
the database of drugs. These drugs were prepared before docking using the LigPrep 
application in Schrödinger Maestro Suite 2014 (LigPrep, version 3.1, Schrödinger, LLC, 
New York, NY, 2014). LigPrep performs optimization of ligand structures viz. 
conversion of structures from 2 dimensional to 3 dimensional, correction of improper 
bond distances, bond orders, generation of ionization states, followed by energy 
minimization. LigPrep generates accurate, energy minimized 3D molecular structures. 
LigPrep also applies sophisticated rules to correct Lewis structures and to eliminate 
mistakes in ligands to reduce downstream computational errors. LigPrep optionally 
expands tautomeric and ionization states, ring conformations, and stereoisomers to 
produce broad chemical and structural diversity from a single input structure. The ligand 
structures prepared by LigPrep were used for Induced Fit Docking. 
• The Induced Fit Docking (IFD)86 application in Schrödinger was used to perform 
flexible protein-ligand docking in our study (Schrödinger Suite 2014-3 Induced Fit 
Docking protocol; Glide version 6.4, Schrödinger, LLC, New York, NY, 2014; Prime 
version 3.7, Schrödinger, LLC, New York, NY, 2014). The IFD application in 
Schrödinger is based on a combination of Grid-based Ligand Docking with Energetics 
(GLIDE)84. The binding site residues are used to generate the receptor grid of the 
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protein.  For the Glide docking stage, extra precision (XP) was selected along with the 
default cut-off of docking of docked poses within 30 kcal/mol of the best-docked 
conformation and which are among the top 20 poses. The poses are ranked using Glide 
score (kcal/mol) and IFD score (kcal/mol). Glide score (GScore) is calculated by the 
software as 
GScore = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + BuryP + RotB + Site, 
wherein vdW = Van der Waals energy, Coul = Coulomb energy, Lipo = Lipophilic term, 
Hbond = Hydrogen-bonding, Metal = Metal-binding term, BuryP = Buried Polar 
groups’ penalty, RotB = Penalty for rotatable bonds that have been frozen, Site = active 
site polar interactions. IFD score is calculated by the software as IFD Score = 1.0*Glide 
Score. We have selected the best-ranked conformation of each ligand. The top 
compounds with Scores (-8.5) and below chosen for their physiochemical properties 
evaluation. 
4.3 Physicochemical properties evaluation 
SwissADME87 was used to predict the drug-likeness nature and the medicinal chemistry 
friendliness of the compounds. SwissADME web interface is developed and maintained by the 
Molecular Modeling Group of the Swiss Institute of Bioinformatics (http://www.sib.swiss).88 It is 
a free web-based software that was used to predict ADME parameters, compute physicochemical 
descriptors and pharmacokinetic properties. 2D structural models were drawn directly into the 
Marvin JS sketcher window and then converted to the SMILES format. SwissADME uses the 
SMILES format to predict these properties. Based on their respective absorption, distribution, 
metabolism, and excretion (ADME) properties and drug-likeness were determined if a compound 
will be an efficient drug nominee. The top 10 compounds that showcased to be efficient drug 
nominees were taken for their cytotoxic and biological evaluation in vitro. 
4.4 Cytotoxic studies of the best MetAP2 inhibitors 
HCT116, HT29, and non-malignant CRL1790 cells were tested using the sulforhodamine B (SRB) 
assay in general as described in the literature.89 The experiments were performed in triplicates. 
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Five thousand cells were plated per 100 µL (microliter) of McCoy’s media at a concentration of 5 
x 104 cells/mL in each well of a 96-well plate (Plate 1- Tz- control plate, Plate 2- Tc- test plate) 
and kept in an incubator for 24 hours. After 24 hours, Tz was treated with 25 µL of 50% w/v 
trichloroacetic acid (TCA) and incubated at 4 °C for 1 hour and then washed with water four times 
and kept to dry at room temperature. Whereas after 24 hours, Tc was treated with cytotoxic agents. 
5- Fluorouracil (5-FU) was taken as a positive control and dimethyl sulfoxide (DMSO) was taken 
as a negative control. To test the compounds a range of dilutions was prepared in DMSO. The 
range of dilutions was of five concentrations of positive controls from 100 µM to 0.001 µM using 
ten-fold serial dilution in 10% (V/V) DMSO and the other 90% is the McCoy’s media. 10 μl test 
sample in 10% (V/V) DMSO was added to each compound well of respective concentrations in 
the 96-well tissue-culture plate in triplicate. Then 10 μl of 10% (V/V) DMSO was added into each 
negative-control well and 10 μl 5-FU of 10% (V/V) DMSO was added into each positive-control 
well. The tests were carried out in triplicates and the different concentrations of the compound 
were added to the 96 multi-well plates and were left for incubation for 48 hours. After 48 hours, 
the Tc plate was treated with 50 µL of 50% W/V TCA and incubated at 4 °C for 1 hour and then 
washed with water four times and left to dry at room temperature. Upon drying 100 µL of SRB 
solution was added to each well and stained at room temperature for 15 minutes then it was washed 
with 1% acetic acid about 5 times and kept at room temperature to dry for 24 hours. The cells are 
washed and stained with SRB solution to monitor the change in adherent cell density. The attached 
stain was solubilized by adding 200 µL of 10 mM Trizma base solution to each well. The colour 
absorption was measured after solubilization with Trizma base for 5 minutes on a microplate 
shaker (room temperature 25 °C, 100 rpm) and the absorbance was measured using a microplate 
reader at 515 nm. The optical density (OD) of SRB in each well is directly proportional to the cell 
number and therefore cell growth can be calculated using the formula below:  




The fluorescence values resulting from normalized cell numbers were plotted against the drug 
concentrations tested to obtain IC50 values with GraphPad Prism 8.1.0 software (GraphPad 
Software, San Diego, CA, USA).  
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4.5 Cell lysate preparation:  
This procedure was performed at 4 °C. Cells after collection were washed twice in Phosphate 
Buffer Saline (PBS) and lysed in ice-cold , modified radioimmunoprecipitation assay (RIPA) 
buffer [0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, 0.1% deoxycholate, 0.15 M sodium 
chloride, 10 mM sodium phosphate (pH 7.0), 100 lM sodium vanadate, 50 mM sodium fluoride, 
50 µM leupeptin, 1% aprotinin, 2 mM EDTA, and 1 mM dithiothreitol].90 Lysates were incubated 
on ice for 15 minutes and then centrifuged at 14,000 rpm for 5 minutes at 4 °C and the supernatant 
obtained was used for western blot analysis. 
4.6 Western blot analysis of MetAP2 expression 
4.6.1 Protein estimation 
Protein concentrations were determined by the Bradford method91 using bovine serum albumin 
(PI37525, Thermo Fisher Scientific)  as a standard.  
4.6.2 SDS PAGE 
10% SDS- polyacrylamide gel was used to separate the proteins isolated from normal human cells 
and human colon cancer cells using Laemmli’s procedure.92 
4.6.3 Western blot analysis 
MetAP2 expression in colon cancer tissues (HCT116 and HT29) was determined by the 
immunoblotting method of Towbin et. al.93 Equal quantities of total protein were loaded and 
separated by 10% SDS-PAGE. The electrophoresed proteins were then blotted onto a 
polyvinylidene difluoride membrane (PVDF, Catalogue#: 1620177, Bio-Rad), then blocked with 
5% w/v non-fat dry milk (Catalogue#: 1706404XTU, Bio-Rad) in Tris-buffered saline with 0.1% 
Tween 20 (TBS-T). The membranes were incubated overnight at 4 °C with anti-Met-AP2 
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antibodies (MetAP2 (D3I1H) Rabbit mAb #12547, 1:1000, and molecular weight 63 kDa, Cell 
Signaling Technology). The samples were washed with TBS-T and then treated with 
corresponding secondary antibody (Anti-rabbit IgG, HRP-linked antibody #7074, 1:1000, Cell 
Signaling Technology) for 2 hours at room temperature. Quantification of the western blot bands 
was performed using the Bio-Rad ChemiDoc imaging system with Clarity™ western ECL 
substrate (Catalogue #: 1705060, Bio-Rad). Both chemiluminescence (CL) and colorimetric 
detection methods were used for imaging western blot.  The PVDF membrane was then be 
subjected to a stripping buffer to facilitate accurate detection of the second protein.94 The 
membrane was washed with TBS-T and then blocked with 5% w/v non-fat dry milk in TBS-T. It 
was then treated with HRP-linked mouse anti-β-actin antibody (sc-8432, molecular weight- 42 
kDa, 1:40,000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at room temperature for 1 h. 
Quantification of the western blot bands was performed using the Bio-rad ChemiDoc imaging 
system with both chemiluminescence and colorimetric detection methods for imaging western 
blot.   
4.7 Statistical Analysis 
Statistical analysis was undertaken to find the correlation between the cytotoxic properties and 
MetAP2 inhibitors using IBM SPSS Statistics 26 software.95 Using the program, with variables of 
HT29 IC50, HCT116 IC50, docking score (aka GScore), molecular weight (MW), LogP, and 
topological polar surface area (TPSA) the data was evaluated. The bivariate linear models with 
logarithmic transformations that were taken for interpretation were linear model, linear-log model, 
and log-log model. The models were used for statistical significance using the Student’s t-test for 
paired data. Dunnett’s post hoc test was also performed to compare both the treatment regime of 
NC 1773 and NC 1768 with control (cells with absence of treatment). A p<0.05 was recorded as 
statistically significant.    
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CHAPTER – 5  
RESULTS AND DISCUSSION 
5.1 Database and Docking studies 
A literature survey for potent curcumin analogs was completed and the creation of a database of 
potent cytotoxic curcumin analogs was made. The library of compounds was a total of 130 
compounds. An experiment was run using the library of compounds and docked against the 
MetAP2 binding pocket. The docking scores (aka GScore) were recorded (ranging from -1 to -10). 
The more negative the docking score the better fit of the compound in the receptor pocket. The 
docking scores of -8.5 and below were taken for physicochemical properties evaluation. 
The docking study targeted PDB: 6QED to examine the potential mode of action of the small 
compounds as anticancer agents targeting the MetAP2 active site. The ligand-protein interactions 
were estimated based on the docking score (aka GScore) using the functions implemented in the 
Induced Fit Docking application in Schrödinger Suite 2014. The docking scores of the top 10 
compounds are presented in Table 1. The compound NC 1773 had a docking score of -9.606 while 
NC 1768 had a docking score of -9.523. All compounds were redocked into active sites in the 
absence of the reference inhibitor. The ligands were well complexed with active sites of the 
enzyme.  
A recent published study reveals the synthesis and screening of a series of quinoline conjugates 
for cytotoxic activity using the NCI-60 screen.96 A single concentration of compound was 
used. The screening results portrayed that few conjugates were moderately effective against the 
Renal Cancer cell line UO-31. The data acquired from biological studies was further validated by 
molecular docking studies (compounds were docked against the active site of the enzyme MetAP-
2) and pharmacokinetic evaluation. The docking studies results inferred that the compounds 
interact with enzyme h-MetAP2 (human-MetAP2) by forming hydrogen bonds in stable 
conformations as compared to the ligand. Notably, the compounds had same H-bonding interaction 
with same amino acid HIS231 as that of ligand. The good interaction seen at docking studies was 
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then validated by the pharmacokinetic evaluation revealing that physiochemical properties were 
in good agreement with the Lipinski's rule of five.81   
5.2 Physicochemical properties evaluation  
The leading compounds from docking studies were taken for pharmacokinetic and drug-likeness 
studies. For any bioactive molecule to be considered as a potential drug, it should possess low 
toxicity with good pharmacokinetic properties. This process was improved based on the high-
throughput animal models and while evaluating the toxicity of the drug candidate. The drug 
likeliness and pharmacokinetic parameters for the compounds were obtained using the 
SwissADME web interface, developed and maintained by the Molecular Modeling Group of the 
Swiss Institute of Bioinformatics. 
The drug-likeness was evaluated based on the Lipinski rules and the Ghose, Veber, Egan, and 
Muegge parameters. The more the number of violations the more likely that a compound won’t 
work in vivo. The colored zone in the SwissADME column of the table given below is the suitable 
physicochemical space for oral bioavailability. In this, 6 parameters are taken as prime indicators: 
• LIPO (lipophilicity): -0.7 <XLOGP3 <+5.0;  
• POLAR (polarity): 20A2 <TPSA< 130A2;  
• INSOLU (insolubility): 0< Log S (ESOL) <6;  
• SIZE: 150g/mol <MW <500g/mol;  
• INSATU (insaturation): 0.25< Fraction Csp3< 1  





Table 5.1: Docking Score and physicochemical properties evaluation 
Mol. # NC # 
Docking 
Score 
Structure SwissADME MW TPSA LogP 
1)  1773  -9.606 
 
 
458.38 46.61 5.44 
2)  1768 -9.523 
 
 
401.28 43.37 5.48 
32 
 
3)  1763 -9.466 
 
 
366.84 43.37 4.95 
4)  1769 -9.429 
 
 
423.93 46.61 4.93 
5)  2383 -9.119 
 
 
266.29 57.53 3.01 
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6)  1780 -8.974 
 
 
389.49 46.61 4.43 
7)  1771 -8.969 
 
 
407.48 46.61 4.71 









9)  1766 -8.778 
 
 
350.38 43.37 4.74 
10)  1792 -8.591 
 
 
393.48 55.84 4.03 
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The topological polar surface area (TPSA) is another important pharmacokinetic parameter that 
predicts the permeability of the membrane by polar atoms.97 The passive absorption value is 20A2 
<TPSA< 130A2. NC 1773 has a TPSA of 46.61 and NC 1768 has 43.37 as its TPSA. Both the 
compounds NC 1773 and NC 1768 had a LogP value of 5.44 and 5.48, respectively. Table 5.1 
consolidates the most prominent parameters for the compounds to be good candidates for 
biological evaluation. Based on the above characteristics, we can conclude that the top 10 
compounds may have good oral bioavailability as well.  
5.3 Biological evaluation 
The top 10 compounds that showcased to be efficient drug nominees from the docking studies and 
their respective physicochemical properties evaluation were taken for their cytotoxic and 
biological evaluation in vitro. 
5.3.1 Cytotoxic Studies:  
The compounds were tested against HCT116 and HT29 cell lines using sulforhodamine B (SRB) 
assay. Their respective cytotoxic profiles are given in the Table 5.2 below.  
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IC50 in µM 
(mean± sd) 
HCT116 
IC50 in µM 
(mean± sd) 
1)  1773  
 
5.51± 0.11 4.21± 0.57 
2)  1768 
 
0.24± 0.14 0.57± 0.59 
3)  1763 
 
0.54± 0.33 1.02± 0.29 
4)  1769 
 
17.63± 1.18 9.21± 0.88 
5)  2383 
 




6)  1780 
 
4.99± 1.91 0.19± 0.33 
7)  1771 
 
0.32± 0.06 0.15± 0.04 
8)  1764 
 
3.95± 0.28 0.05± 0.08 
9)  1766 
 
6.06± 0.57 27.90± 0.55 
10)  1792 
 
1.12± 0.09 0.37± 0.03 
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The top 2 compounds from the cytotoxicity studies were taken for screening against the non-
malignant CRL1790 cells. A comparison of cytotoxicity for the best 2 compounds was made and 
it was deduced from Table 5.3 that the compound 1773 is not selective in nature between non-
malignant CRL1790 and HT-29 cell line as they have the similar kind of cytotoxic profiles, 
whereas in HCT-116 cell line it is more cytotoxic and selective than in non-malignant CRL1790 
cell line. Compound 1768 is also not selective in nature between non-malignant CRL1790 and 
HCT-116 cell line as they have the similar kind of cytotoxic profiles, whereas in the HT-29 cell 
line it is cytotoxic and selective than in non-malignant CRL1790 cell line. All the cytotoxicity 
results of the studied compounds were compared with the results of the 5FU as the reference drug. 
 




 NC 1773 NC 1768 





CRL1790 14.74± 0.88 4.70± 0.33 0.02± 0.01 
HT29 15.36±0.65 5.51± 0.11 0.24± 0.14 
HCT116 4.02±0.48 4.21± 0.57 0.57± 0.59 
a 
The IC50 value in µM (mean± sd) is the concentration of the compound required to inhibit 
the growth of the cells by 50%. 
b 
5FU refers to 5-fluorouracil. 
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Four compounds out of the ten best compounds were previously included in the NCI screening 
program.98  The NC Number with their respective NCI numbers are as follows: 
a) NC 1773  NCI # 693443 
b) NC 1768  NCI # 693441  
c) NC 1763  NCI # 693439 
d) NC 1780  NCI # 697443 
The NCI screening evaluated the compounds against approximately 60 neoplastic cell lines from 
nine different clusters of cancers namely leukemia and melanoma as well as non-small cell lung, 
colon, CNS, ovarian, renal, prostate, and breast cancers.98  The two non-Mannich bases display 
very weak potency with average GI50 (the concentration that causes 50% growth inhibition) values 
of >96.0  uM (1763, 1768). The average GI50 value for melphalan is 19.1 uM and for 5-FU it is 
29.5 uM with 3/57 cell lines having GI50 values of greater than 251 uM. 
On the other hand, the average GI50 figures for the Mannich bases 1773 and 1780 are 3.89 uM and 
1.98 uM, respectively.98 In both cases, colon cancer cells and leukemic cells are very sensitive to 
these two molecules. With these details of bio-evaluations, we can deduce that NC 1773 in 
comparison to NC 1768 has both desirable IC50 and GI50 values for it to be a better candidate in 
being a potent anticancer agent for the treatment of colon cancer.  
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5.3.2 Western Blot Analysis:  
MetAP2 plays a crucial role in the tumor progression of cancer. Previously in a study, MetAP2 
mRNA expression was increased by fumagillin.18 The authors speculated that it may have been an 
adaptive effect due to inhibition of MetAP2 activity. In our previous study we had demonstrated a 
high expression of MetAP2 in human colorectal adenocarcinoma and these findings represent the 
first description of increased MetAP2 expression in colorectal tumors.79 In addition, with the 
moderate staining of MetAP2 in polyps exhibited the use of MetAP2 as a novel biomarker for the 
early detection of colorectal adenocarcinoma using the immunohistochemical approach.2  
NC 2213, a drug design strategy by Pati et. al. was initiated to undertake structural modification 
of curcumin to produce novel synthetic analogs as anticancer agents.78 These enones were 
designed as thiol alkylators. HT29 cells were treated with NC2213 for 48 hours at a 
concentration range of 0 to 5.0 μM for 96 hours to confirm a dose-dependent inhibitory effect. 
HT29 cells displayed a significant decrease in MetAP2 expression, this was validated by western 
blot analysis. Western blot analysis revealed that the MetAP2 expression was inhibited dose-
dependently by the treatment of NC2213 using HT29 cells with an IC50 value of 1.2 μM.
79 The 
early investigation of the mode of action of NC 2213 revealed that it is also a potent inhibitor of 
MetAP2 in HT29 colon cancer cell line.  
The best 2 compounds (1773 and 1768) were analyzed for their inhibitory property against 
MetAP2 protein expression in the HT29 cell line using western blot analysis. The literature survey 
had already shown that MetAP2 has a higher expression in the HT29 rather than the HCT116 cell 
lines making it the cell line of choice for the analysis. The results indicated that protein expression 
was reduced by NC 1773 against the HT29 cell line. The lane with NC 1773 at IC50 value showed 
the maximum reduction of expression while the lanes with NC 1773 at 2 times IC50 and ½ of IC50 
showed about half the reduction in expression of the protein. The lanes with varying concentration 
of NC 1768 showed no reduction in expression of the MetAP2 protein. The experiment was carried 
out in technical and biological duplicates. 5-FU and DMSO lanes were taken as standard. The 
control lane here are untreated HT29 cells. The β-actin served as an internal control. Each lane of 
an SDS-polyacrylamide gel was loaded with 30 µg of protein. The gel was then immunoblotted 
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with anti-MetAP2 primary and secondary antibodies for identifying the MetAP2 band. The 
membrane was then stripped and immunoblotted with an anti-β-actin antibody for identifying the 
β-actin band as described in “Methodology”. The western blot analysis results are shown in Figure 
5.1 with the blue marking for the MetAP2 band at 63kDa and the orange marking for the β-actin 
band at 42kDa.  
Figure 5.2 shows the comparison of effects on protein expression between the MetAP2 band and the 
β-actin band by quantitative analysis of the respective bands using the imaging software from NIH 
(http://rsb.info.nih.gov/nih-image/download.html). The control lane here are untreated HT29 cells 
while β-actin served as an internal control. The data presented as the mean (± SE) of at least two 
separate technical and biological experiments and * depicts the statistical significance (P < 0.05) 
compared to control by Dunnett’s Post Hoc analysis. 
In Figure 5.4 we can see the histogram depiction of the quantitative analysis of the MetAP2 band 
(normalized to β-actin) from the western blot analysis. This analysis was carried out with imaging 
software from NIH. The western blot analysis of extracts from HT29 cells with anti-MetAP2 
antibody was carried out with 30µg of protein loaded in each lane of an SDS-polyacrylamide gel 
and immunoblotted with anti- MetAP2 antibody for imaging the MetAP2 band as described in 
“Methodology.” Dunnett’s Post Hoc analysis determined the statistical significance (P < 0.05) 
compared to control. The control lane here are untreated HT29 cells with β-actin as an internal 
control.  
The identification of novel MetAP2 inhibitors in colon cancer cells has provided with new 
opportunities for preventive or therapeutic interventions by rational drug design. With the details 
of bio-evaluations, we had deduced that NC 1773 in comparison to NC 1768 had both desirable 
IC50 and GI50 values for it to be a better candidate in being a potent anticancer agent for the 
treatment of colon cancer. In comparison of the IC50 values against the non-malignant colon cells, 
compound 1768 showed to be highly cytotoxic to normal cells making compound 1773 as the 
compound of choice for further evaluations. Now, with the western blot analysis results, we can 
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further strengthen the possibility of developing NC 1773 as a MetAP2 specific inhibitor, which 
may be therapeutically useful.  
 
Figure 5.1: Western blot analysis of effects on MetAP2 expression in HT29. Each lane of 
SDS-polyacrylamide gel was loaded with 30 µg of protein. The gel was then immunoblotted 
with anti-MetAP2 primary and secondary antibodies for imaging the MetAP2 band. The control 
here are untreated HT29 cells. The β-actin served as an internal control. The analysis was carried 
out as described in “Methodology”. The blue marking is for the MetAP2 band at 63kDa and the 
orange marking for the β-actin band at 42kDa. The data presented here are representative of at 
least two separate technical and biological experiments. 




Figure 5.2: Comparison of effects on protein expression. Quantitative analysis of the MetAP2 
protein (     ) and β-actin (      ) detected by western blot analysis was carried out with imaging 
software from NIH (http://rsb.info.nih.gov/nih-image/download.html). The control here are 
untreated HT29 cells. The β-actin served as an internal control. The data presented as the (mean ± 
SE) of at least two separate experiments and * depicts the statistical significance (P < 0.05) 
compared to control by Dunnett’s analysis.  












































Figure 5.3: Quantification of western blot. Quantitative analysis of the MetAP2 band 
(normalized to β-actin) was detected by western blot analysis was carried out with imaging 
software from NIH (http://rsb.info.nih.gov/nih-image/download.html). The data presented as the 
(mean ± SE) of at least two separate technical and biological experiments and * depicts the 
statistical significance (P < 0.05) compared to control by Dunnett’s analysis. The western blot 
analysis of extracts from HT29 cells with anti-MetAP2 antibody was carried out with 30µg of 
protein loaded in each lane of an SDS-polyacrylamide gel and immunoblotted with anti- MetAP2 
antibody for imaging the MetAP2 band as described in “Methodology.” 









































5.4 Ligand Receptor Interaction 
The best 2 compounds were screened against the MetAP2 recombinant protein. The MetAP2 
protein structure is shown below in Figure 5.4. It is a monomer containing 365 residues and a total 
structure weight of 43.37 kDa.  The docking images for the ligand-receptor interaction were taken 
at 3 Å rendering it to be a good inhibitor of MetAP2. In Figure 5.5 we can see the interaction of 
compound 1773 with the receptor pocket. The 2 benzene rings are forming polar interactions with 
the HIS 231 amino acid residue, and HIE 339 (histidine neutral ε-protonated rotamer). The ketone 
group is responsible for coordinating with the metal ion both MN507 and MN508, forming the 
primary binding required for the compound to be bioactive.  
 
Figure 5.4: Structure of MetAP2 recombinant protein. The enzyme is a monomer containing 




Figure 5.5: Ligand receptor interaction of compound NC 1773. The ketone group is 
coordinating with both metal ions (grey) and the 2 benzene rings are forming polar interactions 





Figure 5.6: Ligand receptor interaction of compound NC 1768. The ketone group is 
coordinating with MN 507 (grey) and the 2 benzene rings are forming Pi-Pi stacking interactions 




From Figure 5.6 we can see the interaction of compound 1768 with the receptor pocket. The 2 
benzene rings are forming polar interactions with the HIS 231 amino acid residue, and HIE 339. 
The ketone group is responsible for coordinating with the metal ion MN507, forming the primary 
binding required for the compound to be bioactive. While the interaction with the amino residues 
is the same for both the compounds, the ability of compound 1773 to coordinate with 2 metal ions 
contributes it to be more bioactive than 1768 and this is well depicted in the biological evaluations 
as well.   
In Figures 5.7 and 5.8, the visual representations of the compounds 1773 and 1768 docked into the 
binding pocket show that both the compounds have very good docking in the receptor pocket with 
good amino acid residue interactions and coordination with the metal ions. In figure 5.8 there is a 
special indication of the amino acid residues and the metal ions proposed to be vital in the 
























5.5 Statistical analysis of correlation between cytotoxicity and physiochemical properties 
Using the program IBM SPSS Statistics 26, the data for the 10 compounds in Table 5.1 and 5.2 
with variables of HT29 IC50, HCT116 IC50, docking score, molecular weight (MW), LogP, and 
topological polar surface area (TPSA) were evaluated for correlations by Student’s t-test for paired 
data. Statistical analysis was undertaken to find the correlation between the cytotoxicicity (IC50) 
and different physicochemical properties. The bivariate linear models with logarithmic 
transformations that were taken for interpretation were linear model, linear-log model, and log-log 
model. The models were used for statistical significance using the Student’s t-test for paired data. 
A p<0.05 was recorded as statistically significant. The results indicated that none of the parameters 
were significantly correlated with the cytotoxicity of the compounds. The complete result of the 3 
models is given in Table 5.4. The data are expressed as the Pearson’s correlation coefficient.  




Linear model DockingScore TPSA MW LogP 
IC50_HT29 0.209 -0.020 0.165 0.033 
IC50_HCT116 -0.197 -0.217 -0.125 0.056 
 
Linear-Log model DockingScore TPSA MW LogP 
LogIC50_HT29 -0.046 0.131 -0.085 -0.208 
LogIC50_HCT116 0.252 0.056 -0.028 0.001 
 
Log-Log model LogDockingScore LogTPSA LogMW Log_LogP 
LogIC50_HT29 -0.043 0.139 -0.115 -0.203 
LogIC50_HCT116 0.249 0.054 -0.064 -0.032 
a 
The data are expressed as the Pearson’s correlation coefficient with p<0.05 as the critical 
level of significance.  
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CHAPTER – 6  
CONCLUSIONS 
Colorectal cancer is one of the major causes of death worldwide. Designing of target-specific 
molecules has brought better success in developing new anticancer agents. In the present study we 
mainly focused on the investigation of curcumin analogs as novel anticancer molecules targeting 
the active site of MetAP2. 
NC 2213, a drug design strategy by Pati et. al. to undertake structural modification of curcumin to 
produce novel synthetic analogs as anticancer agents demonstrated a significant decrease in 
MetAP2 expression, which was validated by western blot analysis.78 The dienone pharmacophore 
was the alkylating active site where thiol could react with the electron-deficient olefinic carbon 
atom to cause the inhibition of the enzyme. This data suggested the importance of pursuing 
curcumin analogs as potential cytotoxic agents targeting MetAP2. 
In the present study, 130 compounds were docked against MetAP2 enzyme and out of these the 
top 10 compounds that showed good results for their physicochemical properties assessment were 
taken for cytotoxic evaluation. Among the 10 compounds, 2 compounds (NC 1768 and NC 1773) 
had good IC50 profiles, and they were analyzed using a western blot. The western blot indicated 
that protein expression was reduced for NC 1773 against HT-29 cell line.   
Once the validation procedures, protocols were in place, and the library of compounds was ready 
we were able to get the best compounds from their docking scores and the pharmacokinetic 
properties to be tried in vitro against HT-29, HCT-116, and CRL-1790 cells. After this, we were 
able to arrive at one compound, NC 1773 which showed in silico potential to be a very good 
MetAP2 inhibitor. The Student’s t-test for paired data was not significant with p>0.05 in all 3 
bivariate linear models. The result indicates that none of the parameters are critically involved in 
influencing neither the docking nor cytotoxicity or the bioactivity of the compounds. Therefore, 
there is no significant linear or non-linear relationship that exists between the independent and 
dependent variables as p>0.05. 
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The identification of novel MetAP2 inhibitors in colon cancer cells has provided new opportunities 
for preventive or therapeutic interventions by rational drug design. The compound NC 1773 has 
shown excellent results in docking and western blot analysis. Dunnett’s post hoc test showed 
significance at p<0.05 for the treatment protocol of NC 1773 in comparison with control (cells 
with absence of treatment).  
NC 1773 in comparison to NC 1768 had both desirable IC50 and GI50 values for it to be a better 
candidate in being a potent anticancer agent for the treatment of colon cancer. In comparison of 
the IC50 values against the non-malignant colon cells, compound 1768 showed to be highly 
cytotoxic to normal cells making compound 1773 as the compound of choice for further 
evaluations. Now, with the western blot analysis results, we can further strengthen the possibility 
of developing NC 1773 as a MetAP2 specific inhibitor, which may be therapeutically useful. It 
has an ideal IC50 profile and potential bioavailability which warrants further investigation for the 
mechanism of action of NC 1773. Further studies of this work may also reveal the mechanism of 
action of MetAP2 in colon carcinoma at large.  
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CHAPTER – 7  
FUTURE SCOPE 
NC 1773 and NC 1768 could be screened against MetAP2 recombinant protein to evaluate the 
MetAP2 inhibitory potential of these molecules. MetAP2 activity is determined by hydrolysis of 
methionine-p-nitroanilide as the substrate, as described in literature15, 99, 100, methionine-p-
nitroanilide would be hydrolyzed by MetAP2. The MetAP2 activity assay mixture (total volume 
of 500 µl) contains 50 mM Tris-HCl (pH 7.5), 0.25 mM methionine-p-nitroanilide as the substrate, 
and appropriate concentration of enzyme solution. The mixture would be incubated at 37 °C for 
30 minutes and then left on ice for 15 minutes to terminate the enzyme reaction.  
Spectrophotometric determination of nitroanilide would be carried out at 405 nm. The amount that 
releases 1 μM/min p-nitroanilide would be taken as one unit of activity of aminopeptidase under 
the conditions set for assay. MetAP2 expression and activity would be evaluated using various 
concentrations of these compounds. 
Several different analogs of NC 1773 and NC 1768 could be designed and synthesized for better 
anticancer activity and also see the impact of structural modification on activity. In the cases of 
NC 1773 and NC 1768 interactions with the receptor takes place at two points: 
A) The two aryl rings and the amino acid residues 




Some of the structural modifications could be as follows: 
1. The first proposed modification will be the modification of the linker between both the aryl 
rings. Removal of unsaturated keto group of unsaturated ester portion of the linker to make 
the linker shorter. Only the –O– will be flanked by both the aryl rings. We will be able to 
understand whether the length of the linker has any impact or not on the potency of the 
drug towards MetAP2 inhibition. This will also give some idea of the importance of the 
distance between the aryl rings. The proposed structure is given below: 
 
2. The second structural modification will be aimed to increase the size of the terminal aryl 
ring by the replacement of the terminal aryl ring with a naphthyl group.  Th naphthyl ring 
is a natural choice due to its biological activities and to evaluate whether the bigger size of 





3. The third structural modification will be for the linker portion of the compound. Here we 
propose to change of linker from unsaturated keto-ester to an unsaturated thioester. 
Thioester functionality may increase the strength of the bonding to the manganese ions. 
The structure of the proposed analog is given below: 
 
4. The fourth structural modification is around the substitution of Cl atoms in terminal aryl 
ring. The 3,4-dichloro substituents appear to the best among the aryl groups. We will 
synthesize compounds having different substitution patterns like 2,6-dichloro, and 3,5-
dichloro substituents.  
In addition, 2,4,6-trichloro and 3,4,5-trichloro compounds can also be synthesized to see if 
increased biological activity is associated with the di-chloro substitution pattern; and 
whether the tri-chloro substitution is better than di-chloro substitution. The proposed 




5. The fifth structural modification is also around the substitution of Cl atoms in the terminal 
aryl ring. The placement of bromo and iodo substituents in the terminal aryl ring should be 
considered to evaluate whether the size of the halogen group impacts the binding affinity 
and activity of the drug. The substitutions can be 3,4-dibromo; 3,4-diiodo; 2,6-dibromo; 
2,6-diiodo; 3,5-dibromo and 3,5-diiodo. The proposed structure for the fourth modification 
given above can be used for this structural modification as well.   
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